About this test
The TSP19™ panel can be used as a screening test for patients diagnosed with acute myeloid leukemia (AML) and myelodyplastic syndromes (MDS). This test can also provide prognostic information in MDS.
Analysis of gene mutations in cancer is important to clinical decision-making and can serve as a tool when deciding on suitable treatment options and drug targets.
How is testing performed at GTLDNA?
The TSP19™panel analyses specific regions in 19 genes associated with accute myeloid leukemia (AML) and myelodyplastic syndromes (MDS) and covers the entire coding regions of:
CEPBA, DNMT3A, GATA2, TET2, TP53,
as well as hotspot gene regions:
ASXL1, BRAF, CBL, FLT3, IDH1, IDH2, JAK2, KIT, KRAS, NPM1, NRAS, PTPN11, RUNX1, WT1.
DNA is extracted from blood samples and testing is performed using Massive Parallel Sequencing (Next Generation Sequencing), which allows highly sensitive mutation detection and gene analysis.
More detailed information on how targeted sequencing of DNA in cancer works can be found here.
What kind of sample is required?
This screening test requires a medical blood draw.
The TSP19 TM panel requires genetic counselling from a certified professional and must be handled by a Doctor. Upon confirmation of your order we will send you an email with the Referral forms your doctor or counsellor will complete and return (Fax) to us for approval before your sample collection kit is sent out. The results will be sent directly to the doctor or counsellor who will then discuss them with you.
If you are a family member and/or would like to talk to a genetic counsellor, please contact our customer care team and they will help you to find a qualified professional for the test you are considering.
Medicare rebates may apply.
Note: Your only additional cost will be the blood collection fee that should be arranged with the sample collector during your pathology appointment.